Dexamethasone : Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems
Dexamethasone (DEX) has been widely used to treat a variety of diseases, including autoimmune diseases, allergies, ocular disorders, cancer, and, more recently, COVID-19. However, DEX usage is often restricted in the clinic due to its poor water solubility. When administered through a systemic route, it can elicit severe side effects, such as hypertension, peptic ulcers, hyperglycemia, and hydro-electrolytic disorders. There is currently much interest in developing efficient DEX-loaded nanoformulations that ameliorate adverse disease effects inhibiting advancements in scientific research. Various nanoparticles have been developed to selectively deliver drugs without destroying healthy cells or organs in recent years. In the present review, we have summarized some of the most attractive applications of DEX-loaded delivery systems, including liposomes, polymers, hydrogels, nanofibers, silica, calcium phosphate, and hydroxyapatite. This review provides our readers with a broad spectrum of nanomedicine approaches to deliver DEX safely.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
ACS biomaterials science & engineering - 8(2022), 5 vom: 09. Mai, Seite 1763-1790 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Madamsetty, Vijay Sagar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 10.05.2022 Date Revised 29.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsbiomaterials.2c00026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33968707X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33968707X | ||
| 003 | DE-627 | ||
| 005 | 20231226003443.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsbiomaterials.2c00026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM33968707X | ||
| 035 | |a (NLM)35439408 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Madamsetty, Vijay Sagar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dexamethasone |b Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2022 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Dexamethasone (DEX) has been widely used to treat a variety of diseases, including autoimmune diseases, allergies, ocular disorders, cancer, and, more recently, COVID-19. However, DEX usage is often restricted in the clinic due to its poor water solubility. When administered through a systemic route, it can elicit severe side effects, such as hypertension, peptic ulcers, hyperglycemia, and hydro-electrolytic disorders. There is currently much interest in developing efficient DEX-loaded nanoformulations that ameliorate adverse disease effects inhibiting advancements in scientific research. Various nanoparticles have been developed to selectively deliver drugs without destroying healthy cells or organs in recent years. In the present review, we have summarized some of the most attractive applications of DEX-loaded delivery systems, including liposomes, polymers, hydrogels, nanofibers, silica, calcium phosphate, and hydroxyapatite. This review provides our readers with a broad spectrum of nanomedicine approaches to deliver DEX safely | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a nanomaterials | |
| 650 | 4 | |a tissue engineering | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Mohammadinejad, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Uzieliene, Ilona |e verfasserin |4 aut | |
| 700 | 1 | |a Nabavi, Noushin |e verfasserin |4 aut | |
| 700 | 1 | |a Dehshahri, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a García-Couce, Jomarien |e verfasserin |4 aut | |
| 700 | 1 | |a Tavakol, Shima |e verfasserin |4 aut | |
| 700 | 1 | |a Moghassemi, Saeid |e verfasserin |4 aut | |
| 700 | 1 | |a Dadashzadeh, Arezoo |e verfasserin |4 aut | |
| 700 | 1 | |a Makvandi, Pooyan |e verfasserin |4 aut | |
| 700 | 1 | |a Pardakhty, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Aghaei Afshar, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Seyfoddin, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS biomaterials science & engineering |d 2015 |g 8(2022), 5 vom: 09. Mai, Seite 1763-1790 |w (DE-627)NLM249114623 |x 2373-9878 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:5 |g day:09 |g month:05 |g pages:1763-1790 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsbiomaterials.2c00026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 5 |b 09 |c 05 |h 1763-1790 | ||